All In Biotech

Drug Trial Radar · NCT07908641

Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation

A Phase 1, Open-label, Crossover Study to Evaluate the Relative Bioavailability of Apremilast Extended-release and Immediate Release Formulations in Healthy Adult Participants.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

114

Planned (sponsor's estimate)

Start

Nov 18, 2026

Primary completion

Jan 10, 2027

Study completion Jan 10, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.

Conditions

  • Psoriasis
  • Arthritis, Psoriatic
  • Oral Ulcer

Interventions

  • Apremilast XRDrug

    Participants will receive apremilast XR orally.

  • Apremilast IRDrug

    Participants will receive apremilast IR orally .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve (AUC) from Time Zero extrapolated to Infinity (AUCinf) of Apremilast.Time frame: Pre-dose on Day 1 through Day 4 of each treatment period
  2. Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of ApremilastTime frame: Pre-dose on Day 1 through Day 4 of each treatment period
  3. Maximum Observed Plasma Concentration (Cmax) of Apremilast.Time frame: Pre-dose on Day 1 through Day 4 of each treatment period

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit - Daytona Beach

    Daytona Beach, Florida · Recruiting

  • Fortrea Clinical Research Unit - Dallas

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.